ETFs Investing in Pediatrix Medical Group, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Pediatrix Medical Group, Inc. (MD). The funds are sorted by market value and include details such as issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The compilation aims to provide investors with accessible and diversified opportunities with lower risk.
PEDIATRIX MEDICAL GROUP INC : JEFFERIES CUTS TO HOLD FROM BUY; RAISES TARGET PRICE TO $28 FROM $27
Jefferies has downgraded Pediatrix Medical Group Inc. (MD.N) from a "Buy" rating to a "Hold" rating. Despite the downgrade, the firm increased its target price for the company from $27 to $28. This adjustment reflects a revised outlook from Jefferies regarding the medical group.
Will Earnings Beat and Major Buybacks Change Pediatrix Medical Group's (MD) Narrative
Pediatrix Medical Group (MD) recently reported strong Q2 2026 results with increased sales and net income, alongside significant share repurchases. These actions support per-share metrics amidst ongoing challenges like reimbursement risk and physician cost inflation. While the company projects revenue growth and a fair value of $23.17, indicating a 13% downside, investors should consider varying analyst expectations and the impact of these financial moves on the company's long-term investment narrative.
Will Earnings Beat and Major Buybacks Change Pediatrix Medical Group's (MD) Narrative
Pediatrix Medical Group (MD) recently reported strong Q2 2026 results, with increased sales and net income, alongside significant share repurchases. These actions, particularly the buybacks, are supporting the company's per-share metrics amidst ongoing challenges like reimbursement and labor costs. The article suggests that while these positive developments are notable, investors should remain aware of potential sustained reimbursement pressures and explore various analyst perspectives.
Pediatrix Medical Group, Inc. SEC Filing (Aug 14, 2026)
This article details an SEC Form 144 filing by Pediatrix Medical Group, Inc. (MD) on August 14, 2026. The filing indicates a proposed sale of 18,500 shares of common stock with an aggregate market value of $491,868 by an undisclosed individual, through Merrill Lynch. The securities were acquired through stock plan activity on May 9, 2025, and May 12, 2024.
Pediatrix Medical Group (MD) director receives 472 restricted shares in equity grant
Pediatrix Medical Group director Sylvia Jean Young received a grant of 472 restricted shares of common stock on August 12, 2026, as an increase to her annual equity award. These shares, valued at $26.50 each, will vest on May 7, 2027. Following this grant, Young's direct holdings in Pediatrix Medical Group common stock amount to 48,286 shares.
Pediatrix Medical Group (MD) awards 472-share equity grant to director
Pediatrix Medical Group (MD) director Shirley A. Weis was granted 472 restricted shares of common stock on August 12, 2026, under the company's 2008 Incentive Compensation Plan. These shares, valued at $26.50 each, will vest on May 7, 2027, and increase Weis's direct holdings to 19,095 shares. This equity award is categorized as a neutral filing impact and sentiment, as per the Form 4 filing.
Pediatrix Medical Group (MD) grants 472 restricted shares to director Sansone
Pediatrix Medical Group (MD) director Guy P. Sansone received an equity award of 472 restricted shares on August 12, 2026, priced at $26.50 per share. These shares, granted under the company's Second Amended and Restated 2008 Incentive Compensation Plan, will vest on May 7, 2027. Following this transaction, Sansone's direct holdings in Pediatrix Medical Group amount to 87,416 shares.
Pediatrix Medical Group (MD) director receives 472-share restricted stock grant
John M. Starcher Jr., a director at Pediatrix Medical Group (MD), was granted 472 restricted shares of common stock on August 12, 2026. These shares, valued at $26.50 each, are part of the company's incentive compensation plan and will vest on May 7, 2027. Following this award, Starcher directly holds a total of 73,732 Pediatrix common shares.
Pediatrix Medical Group (MD) director awarded 472 restricted shares and reports trust holdings
Pediatrix Medical Group director Thomas McEachin was granted 472 restricted shares of common stock on August 12, 2026, valued at $26.50 per share, under the company's incentive plan. These shares will vest on May 7, 2027. Following this transaction, his direct holdings increased to 7,668 shares, and he also indirectly holds 66,073 shares through the Thomas A. McEachin Living Trust.
Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio
Pediatrix Medical (MD) is presented as a smart investment due to its strong year-to-date performance, strategic acquisitions, and robust financial metrics like an 11.6% return on invested capital. The company benefits from improved cash collections, a favorable payer mix, and higher patient acuity in neonatology, with further growth expected from expanding telehybrid care and OB hospitalist services. Despite a high debt load, Pediatrix Medical carries a Zacks Rank #2 (Buy) and is projected to see significant earnings and revenue growth in 2026.
Pediatrix Medical Group, Inc. Stock 12‑Month Price Target Cut to $26, Implies 2% Downside
The average 12-month price target for Pediatrix Medical Group, Inc. (MD) stock has been lowered from $26.17 to $26 by 5 analysts, with a range of $21 to $28 per share. This new target suggests a potential 2% downside from the August 12 closing price. The consensus rating among 6 covering analysts has shifted to "Hold," with one "Buy" and five "Hold" recommendations.
Wasatch Advisors LP Boosts Stake in Pediatrix Medical Group, Inc. $MD
Wasatch Advisors LP increased its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 21.9% in the second quarter, holding 2.50 million shares valued at approximately $63.3 million. Institutional investors now own 97.71% of the company's stock, which recently reported strong quarterly earnings, beating revenue and EPS estimates. Analysts maintain a "Hold" rating with a consensus target price of $24.83.
Pediatrix Medical Group (MD) Stock Seems Undervalued While Its 89% Return Raises Questions
Pediatrix Medical Group (MD) has seen an 89% share price return over the past year, yet its stock appears undervalued based on several valuation metrics, including a P/E ratio significantly below the healthcare sector average. Despite a recent share price drop post-earnings, the company passes most valuation checks, suggesting a potential discount due to cautious market sentiment rather than weak fundamentals. The key challenge lies in whether margins and cash generation can withstand ongoing reimbursement and regulatory pressures.
Does Pediatrix’s Modest Profit Uptick Reveal a Deeper Shift in MD’s Efficiency Story?
Pediatrix Medical Group reported a modest profit uptick in Q2 and H1 2026, with increased sales and net income. This suggests improved operational efficiency, but the company's investment narrative remains focused on navigating reimbursement and labor pressures. While share buybacks and earnings growth are positive, potential legislative pressures on its reimbursement model present an ongoing risk.
Is Stronger Q2 2026 EPS From Operations Altering The Investment Case For Pediatrix Medical Group (MD)?
Pediatrix Medical Group (MD) reported stronger Q2 2026 results with increased sales and net income, leading to improved EPS from continuing operations. These results, along with the company's inclusion in Russell 2000 Defensive indexes, support its investment narrative of disciplined cost control in the face of healthcare pressures. However, investors should still consider potential risks such as pushback on admin fees and pricing from hospital partners.
Sei Investments Co. Cuts Stock Holdings in Pediatrix Medical Group, Inc. $MD
Sei Investments Co. reduced its stake in Pediatrix Medical Group Inc. (NYSE:MD) by 19.3% in the first quarter, selling 37,564 shares and retaining 157,407 shares valued at $3.37 million. Despite institutional selling and buying from various firms, the company reported strong Q1 earnings of $0.63 per share, exceeding estimates, with revenue up 4.1% year-over-year. Analysts currently hold a "Hold" rating on the stock with an average price target of $24.83.
Is Stronger Q2 2026 EPS From Operations Altering The Investment Case For Pediatrix Medical Group (MD)?
Pediatrix Medical Group reported stronger Q2 2026 results with increased sales and net income, alongside improved EPS from continuing operations. These results support the company's investment narrative, which relies on demand for maternal-fetal care and cost control, despite ongoing reimbursement and labor pressures. The article also notes Pediatrix's inclusion in defensive indexes and its ongoing share repurchases, while cautioning investors to weigh the risk of pushback on admin fees and pricing from hospital partners.
Does Pediatrix’s Modest Profit Uptick Reveal a Deeper Shift in MD’s Efficiency Story?
Pediatrix Medical Group (NYSE:MD) reported an uptick in its Q2 2026 sales and net income, alongside higher EPS, suggesting improved profitability and operational efficiency. While recent share repurchases and earning improvements may enhance per-share metrics, the company's investment narrative is still significantly influenced by reimbursement risks and hospital fee negotiations. Analysts' varying forecasts highlight the diverse perspectives on Pediatrix's future, with some expecting significantly higher fair values despite current pressures.
Pediatrix Medical Tops Q2 Earnings on Better Cash Collections
Pediatrix Medical Group (MD) reported strong second-quarter 2026 earnings, surpassing analyst estimates due to improved cash collections, a favorable payor mix, and recent acquisitions. Despite higher operating costs and lower patient volumes, the company saw an 18.9% increase in adjusted EPS and a 4.1% rise in net revenues. MD reaffirmed its 2026 guidance for adjusted EBITDA, projecting it to be between $280 million and $300 million.
Pediatrix Medical Tops Q2 Earnings on Better Cash Collections
Pediatrix Medical Group (MD) reported strong second-quarter 2026 results, surpassing earnings and revenue estimates due to improved cash collections and a favorable payor mix, despite facing lower patient volumes and higher operating costs. The company's adjusted EPS increased by 18.9% year over year, and net revenues grew by 4.1%. Management reaffirmed its adjusted EBITDA guidance for 2026 and provided updated estimates for net income and various expenses.
Deutsche Bank Adjusts Pediatrix Medical Price Target to $25 From $19, Maintains Hold Rating
Deutsche Bank has updated its price target for Pediatrix Medical to $25, an increase from the previous target of $19. Despite the raised price target, the firm has decided to maintain its Hold rating on the company's stock. This adjustment reflects an updated valuation while signaling a continued cautious stance on the investment.
Insiders At Pediatrix Medical Group Sold US$1.8m In Stock, Alluding To Potential Weakness
This article analyzes insider selling at Pediatrix Medical Group (NYSE:MD) totaling US$1.8m over the last year, particularly a large sale by the CEO, which could signal potential weakness in the company's future performance. Despite the stock price being down 23% in the past 12 months, this insider selling suggests that company leaders might perceive the current valuation as fair or high, rather than low. The analysis also briefly touches on shareholder returns and the company's debt levels.
Deutsche Bank Adjusts Pediatrix Medical Price Target to $25 From $19, Maintains Hold Rating
Deutsche Bank has updated its price target for Pediatrix Medical Group, Inc. to $25, an increase from the previous $19, while keeping a "Hold" rating on the stock. This adjustment follows the company's Q2 2026 earnings report, which showed rising adjusted earnings and revenue. Pediatrix Medical Group specializes in physician services for newborn, maternal-fetal, and other pediatric subspecialty care, operating both in hospitals and office-based practices.
Pediatrix Q2 2026 earnings: Reimbursement gains offset volume declines
Pediatrix Medical Group (NYSE: MD) reported a 4.0% year-over-year increase in Q2 2026 net revenue to $487.8 million, driven by recent acquisitions and improved reimbursement rates, despite a decline in patient volumes. While diluted GAAP EPS rose to $0.49, higher operating costs led to a decrease in GAAP operating income. The company reaffirmed its full-year 2026 adjusted EBITDA outlook, indicating stable management expectations.
Pediatrix Medical Group’s (NYSE:MD) Q2 CY2026: Beats On Revenue But Stock Drops 12.3%
Pediatrix Medical Group (NYSE:MD) reported Q2 CY2026 results that exceeded revenue and non-GAAP profit expectations, with sales up 4% year-on-year to $487.8 million and adjusted EPS of $0.63. Despite beating estimates, the stock dropped 12.3% post-announcement, indicating investor disappointment. The company highlighted strong performance from recent acquisitions and favorable reimbursement metrics, but long-term revenue growth has been modest, and EPS growth was largely attributed to share buybacks.
Pediatrix Medical Group Q2 2026 Earnings Call Transcript
Pediatrix Medical Group reported solid Q2 2026 results with adjusted EBITDA of $76 million, reaffirming its full-year outlook of $280-$300 million. The company's revenue increased by 4%, driven by strong RCM collections, favorable payer mix, and higher patient acuity, despite a 2% decline in same-unit patient service volumes. Pediatrix also repurchased nearly 2 million shares and plans to pursue growth through tele-hybrid services, obstetric hospitalist programs, and strategic acquisitions, while maintaining a strong balance sheet.
Pediatrix Medical beats Q2 revenue estimates, reaffirms 2026 adjusted EBITDA outlook
Pediatrix Medical Group (NYSE: MD) reported Q2 revenue that beat analyst estimates, driven by recent acquisitions and improved reimbursement factors, despite a decrease in patient volumes. The company also reaffirmed its 2026 full-year Adjusted EBITDA outlook. Analysts currently rate the stock as a "buy" with a median 12-month price target slightly below its recent closing price.
Full Transcript: Pediatrix Medical Group Q2 2026 Earnings Call
Pediatrix Medical Group (NYSE: MD) reported Q2 2026 adjusted EBITDA of $76 million, reaffirming its full-year outlook of $280-$300 million. The company's same-unit revenue grew due to strong RCM collections, improved payer mix, and higher patient acuity, despite a decline in NICU days. Pediatrix also repurchased nearly 2 million shares and is strategically expanding its telemedicine services while seeking growth opportunities with external investors.
Earnings Flash (MD) Pediatrix Medical Group, Inc. Posts Q2 Adjusted EPS $0.63 per Share, vs. FactSet Est of $0.59
Pediatrix Medical Group, Inc. (MD) reported Q2 adjusted EPS of $0.63 per share, surpassing FactSet's estimate of $0.59. The article provides a snapshot of the company's recent performance and mentions its Q2 2026 earnings call scheduled for August 4, 2026. Further details about the company's financial results and recent news are available, though some content is reserved for members.
Pediatrix Medical Group’s (NYSE:MD) Q2 CY2026: Beats On Revenue But Stock Drops 12.3%
Pediatrix Medical Group (NYSE:MD) reported Q2 CY2026 results that exceeded market revenue expectations, with sales up 4% year-on-year to $487.8 million and non-GAAP profit beating consensus estimates. Despite this performance and a positive EBITDA outlook, the stock dropped 12.3% immediately following the results. The company's revenue growth has been modest over the past five years, with recent growth driven by existing locations rather than new ones, while adjusted EPS has seen a boost from stock repurchases.
Earnings call transcript: Pediatrix beats Q2 2026 estimates, shares slip
Pediatrix Medical Group exceeded Q2 2026 earnings and revenue estimates, reporting adjusted EPS of $0.63 on $488 million in revenue, compared to analyst expectations of $0.60 and $478.49 million. Despite the beat, shares slipped 1.1% in early trading, influenced by softer patient volumes and cautious second-half trends. The company reaffirmed its full-year 2026 adjusted EBITDA guidance of $280 million to $300 million, emphasizing its stable core business, strategic telehealth expansion, and strong financial position.
Pediatrix Q2 Revenue Reaches $488M as Same-Unit Volume Falls
Pediatrix Medical Group reported strong second-quarter 2026 results with net revenue of $488 million and Adjusted EPS of $0.63, exceeding expectations. The company attributes this performance to recent acquisitions and improved reimbursement metrics, despite a 2.1% decrease in same-unit patient volume. Pediatrix reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million, highlighting its financial flexibility for growth and strategic opportunities.
Pediatrix Medical Group (MD) Q2 Earnings: What To Expect
Pediatrix Medical Group (MD) is set to report its Q2 earnings this Tuesday. The market expects a 1.9% year-on-year revenue growth, a turnaround from last year's decrease. The company has a strong track record of beating revenue estimates, and analysts have reconfirmed their expectations for the upcoming report.
Pediatrix Medical earnings up next after sector headwinds averted
Pediatrix Medical Group Inc. is expected to report strong second-quarter results, with analysts predicting 60 cents per share on revenue of $478.49 million, signaling significant sequential acceleration. The company has distinguished itself by avoiding the reimbursement pressures affecting other healthcare providers, maintaining a stable payor mix and reaffirming its full-year 2026 Adjusted EBITDA outlook. Investors will be watching for commentary on reimbursement trends, margin expansion drivers, and the durability of its resilience against sector headwinds to determine if its recent stock surge is sustainable.
Pediatrix Medical Group (MD) Q2 Earnings: What To Expect
Pediatrix Medical Group (MD) is set to report its Q2 earnings this Tuesday before market open. Analysts anticipate a 1.9% year-on-year revenue growth, a reversal from last year's 7% decrease, with estimates generally reconfirmed by analysts. The company has a history of beating revenue estimates, and while shares are down 3.2% in the last month, the average analyst price target is $24.50.
Pediatrix Medical Group Inc (MD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Pediatrix Medical Group Inc (MD), focusing on its price momentum, support, resistance levels, and various technical indicators. It notes that MD's current stock price is trading between resistance at $28.32 and support at $24.25, suggesting suitability for range-bound swing trading. The analysis includes a summary of indicators like MACD, RSI, and Moving Averages, with a combined signal of "Neutral" for buying or selling the stock.
Pediatrix Medical Group Inc (MD) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Pediatrix Medical Group Inc (MD), noting its current risk score of 5.98, ranking it 34 out of 75 in the Healthcare Providers & Services industry. The company has a beta value of 0.70, indicating it tends to underperform in up markets but has smaller declines in down markets. The assessment includes data on volatility, maximum drawdown, and return metrics over various periods.
Pediatrix Medical Group Number of Employees 2026 | Employee Count & Headcount Data
Pediatrix Medical Group (NYSE: MD) had approximately 6,607 employees worldwide as of March 2026, marking a 3.3% decline from 2023 but a 0.1% increase year-over-year. The company is actively hiring, with 934 active job postings in 2026, a 46.9% increase from 2025. The workforce is concentrated in the United States, with a median employee tenure of 5.4 years and an average salary of $125,507.
Pediatrix Medical Group, Inc. Revenue Breakdown – BX:PDC
This article provides a revenue breakdown for Pediatrix Medical Group, Inc. (PDC) from TradingView. It highlights that in the last year, the company generated 1.52 billion CHF, primarily from its Neonatal, Maternal-fetal, and Other Pediatric Subspecialty Physician Services segment. The majority of this revenue, 1.52 billion CHF, originated from the United States.
Pediatrix Medical Group Inc (MD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides an overview of Pediatrix Medical Group Inc (MD)'s shareholder structure, detailing major institutional holdings and shareholder types. It lists top shareholders like BlackRock and Vanguard, their respective proportions, and also provides a historical look at institutional shareholding and recent shareholder activity. The article also identifies several ETFs that hold MD shares.
Pediatrix Medical Group Announces General Counsel Leadership Transition
Pediatrix Medical Group announced a leadership transition for its General Counsel position. Mary Ann E. Moore will step down from her roles by year-end 2026 and serve in an advisory capacity until October 31, 2026, with her departure treated as a termination without cause. David Haddock has been appointed as the new Executive Vice President, General Counsel, and Secretary.
Pediatrix Medical Group, Inc. Revenue Breakdown – NYSE:MD
Pediatrix Medical Group, Inc. (NYSE: MD) reported total revenue of $1.91 billion USD last year. The majority of this revenue came from its Neonatal, Maternal-fetal and Other Pediatric Subspecialty Physician Services segment. The United States was the primary contributor to this revenue, accounting for $1.91 billion USD, a decrease from $2.01 billion USD the year prior.
Pediatrix Medical Group Inc (MD) Cash Flow Statement
This article provides a comprehensive cash flow statement for Pediatrix Medical Group Inc (MD), broken down into quarterly and annual data for operating, investing, and financing activities. It details various components like net income, capital expenditures, and changes in working capital, along with frequently asked questions defining each cash flow type and MD's performance in those areas. The data spans from FY2012Q1 through FY2026Q1, offering a long-term financial overview.
How Strong Quarterly Results But Softer Long-Term Returns At Pediatrix (MD) Have Changed Its Investment Story
Pediatrix Medical Group (MD) recently reported strong quarterly results which were well received, despite its long-term revenue growth averaging only 2.1% annually over the past five years and declining return on invested capital. This creates a tension between its current operational strength and future growth prospects. While the recent Q1 beat supports near-term profitability, the article suggests investors should consider the risk of weakening returns on new investments and projected slower, less profitable growth in the long term.
Pediatrix appoints David Haddock as EVP, general counsel, secretary
Pediatrix Medical Group has appointed David Haddock as its new executive vice president, general counsel, and secretary. He replaces Mary Ann E. Moore, who will advise the company until October 31, 2026, before her departure. Moore had previously announced her plans to transition out of her executive roles by the end of the year.
MD4766160 Bond Risk Profile
This page provides a risk profile for the MD4766160 bond, issued by Pediatrix Medical Group, Inc. with a 6.25% coupon maturing on January 15, 2027. It offers an overview of key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, while also mentioning access to analyst ratings.
MD5355101 Bond Risk Profile
The article provides a risk profile for the MD5355101 bond, issued by Pediatrix Medical Group, Inc. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating. The profile aims to help investors evaluate the bond's reliability and make informed decisions.
Pediatrix Medical Group (MD) Soars 7.3%: Is Further Upside Left in the Stock?
Pediatrix Medical Group (MD) shares rose 7.3% following an impressive volume and investor optimism regarding the company's Q2 2026 update. The company confirmed stable payor mix and reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280-$300 million, with expected quarterly earnings of $0.57 per share. Despite the strong price increase, the consensus EPS estimate has remained unchanged, suggesting that sustained upside will depend on future revisions to earnings estimates.
Analysts Offer Insights on Healthcare Companies: Pediatrix Medical Group (MD) and Travere Therapeutics (TVTX)
Healthcare sector analysts have provided insights on Pediatrix Medical Group (MD) and Travere Therapeutics (TVTX). Mizuho Securities maintained a Hold rating on Pediatrix Medical Group with a $27.00 price target, while Wedbush maintained a Buy rating on Travere Therapeutics with a $61.00 price target. The article also mentions TipRanks has launched a new ETF (NYSE:RANK) based on its unique data, tracking 50 large U.S. companies.
